Suppr超能文献

肥胖管理科学:内分泌学会科学声明。

The Science of Obesity Management: An Endocrine Society Scientific Statement.

机构信息

Department of Clinical Obesity, Pennington Biomedical Research Center, Louisiana State University, Baton Rouge, Louisiana.

Institute of Health Metrics and Evaluation University of Washington, Seattle, Washington.

出版信息

Endocr Rev. 2018 Apr 1;39(2):79-132. doi: 10.1210/er.2017-00253.

Abstract

The prevalence of obesity, measured by body mass index, has risen to unacceptable levels in both men and women in the United States and worldwide with resultant hazardous health implications. Genetic, environmental, and behavioral factors influence the development of obesity, and both the general public and health professionals stigmatize those who suffer from the disease. Obesity is associated with and contributes to a shortened life span, type 2 diabetes mellitus, cardiovascular disease, some cancers, kidney disease, obstructive sleep apnea, gout, osteoarthritis, and hepatobiliary disease, among others. Weight loss reduces all of these diseases in a dose-related manner-the more weight lost, the better the outcome. The phenotype of "medically healthy obesity" appears to be a transient state that progresses over time to an unhealthy phenotype, especially in children and adolescents. Weight loss is best achieved by reducing energy intake and increasing energy expenditure. Programs that are effective for weight loss include peer-reviewed and approved lifestyle modification programs, diets, commercial weight-loss programs, exercise programs, medications, and surgery. Over-the-counter herbal preparations that some patients use to treat obesity have limited, if any, data documenting their efficacy or safety, and there are few regulatory requirements. Weight regain is expected in all patients, especially when treatment is discontinued. When making treatment decisions, clinicians should consider body fat distribution and individual health risks in addition to body mass index.

摘要

肥胖症的流行率,通过身体质量指数来衡量,在美国和全球范围内已经上升到了不可接受的水平,这导致了危险的健康隐患。遗传、环境和行为因素都会影响肥胖症的发展,公众和卫生专业人员都对患有这种疾病的人存在污名化。肥胖症与多种疾病相关,并导致寿命缩短、2 型糖尿病、心血管疾病、某些癌症、肾病、阻塞性睡眠呼吸暂停、痛风、骨关节炎和肝胆疾病等。减肥以剂量相关的方式减轻所有这些疾病——减肥越多,效果越好。“医学上健康的肥胖症”表型似乎是一种随着时间推移进展为不健康表型的短暂状态,尤其是在儿童和青少年中。通过减少能量摄入和增加能量消耗来实现最佳减肥效果。有效的减肥方案包括经过同行评审和批准的生活方式改变方案、饮食、商业减肥方案、运动方案、药物和手术。一些患者用来治疗肥胖症的非处方草药制剂的数据有限,即使有,也无法证明其疗效或安全性,而且监管要求很少。所有患者都会出现体重反弹,尤其是在停止治疗时。在做出治疗决策时,临床医生除了考虑体重指数外,还应考虑体脂分布和个体健康风险。

相似文献

1
The Science of Obesity Management: An Endocrine Society Scientific Statement.
Endocr Rev. 2018 Apr 1;39(2):79-132. doi: 10.1210/er.2017-00253.
3
Bariatric surgery: an evidence-based analysis.
Ont Health Technol Assess Ser. 2005;5(1):1-148. Epub 2005 Jan 1.
5
[Pharmacological therapy of obesity].
G Ital Cardiol (Rome). 2008 Apr;9(4 Suppl 1):83S-93S.
8
Pediatric Obesity-Assessment, Treatment, and Prevention: An Endocrine Society Clinical Practice Guideline.
J Clin Endocrinol Metab. 2017 Mar 1;102(3):709-757. doi: 10.1210/jc.2016-2573.
9
Obesity Management in Adults: A Review.
JAMA. 2023 Nov 28;330(20):2000-2015. doi: 10.1001/jama.2023.19897.
10
Review of Childhood Obesity: From Epidemiology, Etiology, and Comorbidities to Clinical Assessment and Treatment.
Mayo Clin Proc. 2017 Feb;92(2):251-265. doi: 10.1016/j.mayocp.2016.09.017. Epub 2017 Jan 5.

引用本文的文献

4
Is obesity the next step in evolution through brain changes?
Neurosci Appl. 2023 Nov 25;3:103927. doi: 10.1016/j.nsa.2023.103927. eCollection 2024.
6
Gastric Remnant Perforation 10 Years After Roux-en-Y Gastric Bypass: A Report of a Rare Case.
Cureus. 2025 May 30;17(5):e85077. doi: 10.7759/cureus.85077. eCollection 2025 May.
7
Editorial: Subjective sensations in obesity and related chronic diseases.
Front Nutr. 2025 Jun 6;12:1625911. doi: 10.3389/fnut.2025.1625911. eCollection 2025.

本文引用的文献

1
Comparative efficacy of five long-term weight loss drugs: quantitative information for medication guidelines.
Obes Rev. 2017 Dec;18(12):1377-1385. doi: 10.1111/obr.12606. Epub 2017 Oct 10.
2
Obesity Pathogenesis: An Endocrine Society Scientific Statement.
Endocr Rev. 2017 Aug 1;38(4):267-296. doi: 10.1210/er.2017-00111.
3
Management of cardiovascular diseases in patients with obesity.
Nat Rev Cardiol. 2018 Jan;15(1):45-56. doi: 10.1038/nrcardio.2017.108. Epub 2017 Jul 27.
5
Beverage Intake During Pregnancy and Childhood Adiposity.
Pediatrics. 2017 Aug;140(2). doi: 10.1542/peds.2017-0031. Epub 2017 Jul 8.
6
Pretreatment fasting plasma glucose and insulin modify dietary weight loss success: results from 3 randomized clinical trials.
Am J Clin Nutr. 2017 Aug;106(2):499-505. doi: 10.3945/ajcn.117.155200. Epub 2017 Jul 5.
7
Pediatric Obesity-Assessment, Treatment, and Prevention: An Endocrine Society Clinical Practice Guideline.
J Clin Endocrinol Metab. 2017 Mar 1;102(3):709-757. doi: 10.1210/jc.2016-2573.
8
Markers of dietary protein intake are associated with successful weight loss in the POUNDS Lost trial.
Clin Obes. 2017 Jun;7(3):166-175. doi: 10.1111/cob.12188. Epub 2017 Mar 24.
9
The New Biology and Pharmacology of Glucagon.
Physiol Rev. 2017 Apr;97(2):721-766. doi: 10.1152/physrev.00025.2016.
10
In Mexico, Evidence Of Sustained Consumer Response Two Years After Implementing A Sugar-Sweetened Beverage Tax.
Health Aff (Millwood). 2017 Mar 1;36(3):564-571. doi: 10.1377/hlthaff.2016.1231. Epub 2017 Feb 22.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验